Clinical Practice Guidelines – Waldenstrom’s Macroglobulinaemia

Published in 2018 - Ann Oncol (2018) 29 (Suppl 4): iv41–iv50
Authors: E. Kastritis, V. Leblond, M.A. Dimopoulos, E. Kimby, P. Staber, M.J. Kersten, A. Tedeschi & C. Buske, on behalf of the ESMO Guidelines Committee

The 2018 ESMO Clinical Practice Guidelines on Waldenström’s Macroglobulinemia (WM) are based on results from recent studies and updated analyses. New recommendations are given regarding the role of MYD88 L265P detection in the diagnosis of WM and the role of ibrutinib in the treatment of symptomatic WM. Updated recommendations on patient-specific and symptom-based treatment selection are given.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings